OBJECTIVE: To determine the magnitude and determinants of weight loss in humans exposed to betahistine, a centrally acting histamine-1 (H-1) agonist and partial histamine-3 (H-3) antagonist. DESIGN: A multicenter randomized, placebo-controlled dose-ranging weight loss trial with a 12-week treatment period. SUBJECTS:Two hundred and eighty-one obese but otherwise healthy participants. MEASUREMENTS: Weight and obesity-related comorbidities at baseline and at the end of the intervention. RESULTS:Betahistine, at the doses tested, did not induce significant weight loss. With the exception of headache, no difference in adverse effect profile was noted between placebo and treatment groups. Subgroup analysis revealed that age below 50 years, ethnicity (non-Hispanics) and gender (women) were the strongest predictors of weight loss in this population. When these three factors were combined together, the betahistine 48 mg group (n=23) lost -4.24+/-3.87 kg, whereas the placebo group (n=25) lost -1.65+/-2.96 kg during this time period (P=0.005). CONCLUSION:Betahistine, at the doses tested, induced significant weight loss with minimal adverse events only in women below 50 years.
RCT Entities:
OBJECTIVE: To determine the magnitude and determinants of weight loss in humans exposed to betahistine, a centrally acting histamine-1 (H-1) agonist and partial histamine-3 (H-3) antagonist. DESIGN: A multicenter randomized, placebo-controlled dose-ranging weight loss trial with a 12-week treatment period. SUBJECTS: Two hundred and eighty-one obese but otherwise healthy participants. MEASUREMENTS: Weight and obesity-related comorbidities at baseline and at the end of the intervention. RESULTS:Betahistine, at the doses tested, did not induce significant weight loss. With the exception of headache, no difference in adverse effect profile was noted between placebo and treatment groups. Subgroup analysis revealed that age below 50 years, ethnicity (non-Hispanics) and gender (women) were the strongest predictors of weight loss in this population. When these three factors were combined together, the betahistine 48 mg group (n=23) lost -4.24+/-3.87 kg, whereas the placebo group (n=25) lost -1.65+/-2.96 kg during this time period (P=0.005). CONCLUSION:Betahistine, at the doses tested, induced significant weight loss with minimal adverse events only in women below 50 years.
Authors: Jolene Zheng; Joseph R Vasselli; Jason F King; Michael L King; Wenqian We; Zachary Fitzpatrick; William D Johnson; John W Finley; Roy J Martin; Michael J Keenan; Frederic M Enright; Frank L Greenway Journal: Am J Ther Date: 2016 Nov/Dec Impact factor: 2.688
Authors: Asem H Ali; Lisa B Yanoff; Elizabeth A Stern; Abena Akomeah; Amber Courville; Merel Kozlosky; Sheila M Brady; Karim A Calis; James C Reynolds; Melissa K Crocker; Nir Barak; Jack A Yanovski Journal: Am J Clin Nutr Date: 2010-09-29 Impact factor: 7.045
Authors: Robert C Smith; Lawrence Maayan; Renrong Wu; Mary Youssef; Zhihui Jing; Henry Sershen; Victoria Szabo; Jordan Meyers; Hua Jin; Jinping Zhao; John M Davis Journal: Psychopharmacology (Berl) Date: 2018-10-31 Impact factor: 4.530
Authors: Giuseppe Di Giovanni; Dubravka Svob Strac; Montse Sole; Mercedes Unzeta; Keith F Tipton; Dorotea Mück-Šeler; Irene Bolea; Laura Della Corte; Matea Nikolac Perkovic; Nela Pivac; Ilse J Smolders; Anna Stasiak; Wieslawa A Fogel; Philippe De Deurwaerdère Journal: Front Neurosci Date: 2016-11-24 Impact factor: 4.677
Authors: Shahira F El-Menshawe; Adel Ahmed Ali; Abdelkhalk Ali Halawa; Ahmed Sg Srag El-Din Journal: Drug Des Devel Ther Date: 2017-11-28 Impact factor: 4.162